Quantum CART (qCART), a piggyBac-based system for development and production of virus-free multiplex CAR-T cell therapy
Chen, Y.-C.; Hua, W.-K.; Hsu, J. C.; Chang, P. S.; Wen, K.-L. K.; Huang, Y.-W.; Tsai, J.-C.; Kao, Y.-H.; Wu, P.-H.; Wang, P.-N.; Chen, K.-F.; Liao, W.-T.; Wu, S. C.-Y.
Show abstract
Chimeric antigen receptor T (CAR-T) cell therapy has the potential to transform cancer treatment. However, CAR-T therapy application is currently limited to certain types of relapsed/refractory B cell lymphomas. To unlock the full potential of CAR-T therapy, technologic breakthroughs will be needed in multiple areas, including optimization of autologous CAR-T development, shortening the innovation cycle, and further manufacturing advancement of next-generation CAR-T therapies. Here, we established a simple and robust virus-free multiplex Quantum CART system that seamlessly and synergistically integrates four platforms: 1. GTailor for rapid identification of lead CAR construct design, 2. Quantum Nufect for effective but gentle electroporation-based gene delivery, 3. Quantum pBac, featuring a virus-free transposon-based vector with large payload capacity and integration profile similar to retrovirus, and 4. iCellar for robust and high-quality CAR+ T memory stem cell expansion. This robust, virus-free multiplex Quantum CART system is expected to unleash the full potential of CAR-T therapy for treating diseases.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.